CNBX Pharmaceuticals Inc. is a Bethesda, Maryland-based clinical-stage biopharmaceutical company focused on cannabinoid-based therapies for cancer. The company’s current lead programs include Cannabics SR, an oral capsule being developed for advanced cancer and cancer anorexia cachexia syndrome, and RCC-33, a first-in-class candidate for colorectal cancer. CNBX has shifted through several prior business models, including mining and oil and gas, and has operated as a biotech company since 2014. Its research and development work has been conducted through licensed facilities in Israel, while commercialization is intended to rely on licensing and third-party partners rather than an internal sales force. The company is still pre-commercial and has not generated meaningful product revenue from its drug pipeline.
−100,0 %
0.01
0.01
| % | |
|---|---|
| Lead drug candidates | 0% Clinical and pre-clinical oncology assets such as Cannabics SR and RCC-33. |
| Research and development platform | 0% Discovery work on cannabinoid-based therapies and administration routes for cancer. |
| Licensing and partnering | 0% Potential commercialization model based on out-licensing and strategic collaborations. |
| Contract laboratory services | 100% Historical laboratory services revenue generated outside the core drug pipeline. |
CNBX’s direct customers are not yet established in the way they would be for a commercial pharmaceutical company,...
Research institutions, CROs, and trial collaborators that support preclinical and Phase I/II development of RCC-33 and other oncology candidates.
Pharmaceutical or biotech companies that may license CNBX intellectual property to commercialize products in the U.S. or abroad.
Oncologists, hospitals, and cancer patients who would be the eventual users of approved cannabinoid-based cancer therapies.
GMP suppliers and outsourced CMC providers that supply active ingredients and technical packages for regulatory filings.
Customers for non-core lab services that produced limited historical revenue while the company was still early stage.
CNBX is headquartered in Bethesda, Maryland in the United States, and its corporate decision-making and financing...
CNBX’s strategy is to advance its oncology pipeline through preclinical work and into first-in-human Phase I/II...
Clinical entry is the key value-creation step for a pre-clinical oncology company and is required to validate the asset.
The company has limited cash flow and needs external capital to fund trials, regulatory work, and operating expenses.
CNBX lacks sales, marketing, and distribution infrastructure, so commercialization depends on third parties.
The most immediate risk is going concern risk, as auditors have expressed substantial doubt about the company’s ability...
Auditors disclosed substantial doubt about the company’s ability to continue as a going concern, and the business requires external capital to fund operations.
RCC-33 is still pre-clinical/early clinical, so efficacy, safety, and trial execution remain unproven.
The company must satisfy FDA requirements for IND filing, clinical trials, and eventual commercialization.
CNBX has no internal sales, marketing, or distribution capability and intends to rely on third parties or licensees.
Research has been conducted in Israel under local licensing, so permissions and cross-border operations are important to execution.
RAPH · Medicinal Chemicals & Botanical Products
NRXP · Pharmaceutical Preparations
ANEB · Pharmaceutical Preparations
CNSP · Pharmaceutical Preparations
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
AGTX · Biological Products, (No Diagnostic Substances)
: 11/08/2026